Abstract
Nitric oxide (NO) is a reactive radical produced by the enzyme nitric oxide synthase (NOS) and it plays an important role in a large number of biological pathways. NO can be produced under normal physiologic conditions and contribute to homeostasis but, when produced in excess, it may lead to tissue injury and organ dysfunction. The regulation of NOS activity and expression is becoming increasingly understood. NOS enzyme inhibitors as tools to decrease excessive NO synthesis have received the most attention and have been subjected to the greatest experimental study. Compounds that scavenge excessive NO have been developed and have shown promise in a number of experimental models but have received considerably less attention as potential therapeutic agents. In this article, the use of NO scavengers in two conditions in which excessive NO appears to be pathophysiologically significant, shock and sepsis, is reviewed. The relevant biology of NO in these disease states is presented and the therapeutic potential of NO scavengers in clinical care is explored.
Keywords: iNOS, Polyaminocarborylate compounds, hemorrhagic shock, endotoxin, Dithiocarbamate
Current Pharmaceutical Design
Title: Therapeutic Use of Nitric Oxide Scavengers in Shock and Sepsis
Volume: 12 Issue: 27
Author(s): Brian G. Harbrecht
Affiliation:
Keywords: iNOS, Polyaminocarborylate compounds, hemorrhagic shock, endotoxin, Dithiocarbamate
Abstract: Nitric oxide (NO) is a reactive radical produced by the enzyme nitric oxide synthase (NOS) and it plays an important role in a large number of biological pathways. NO can be produced under normal physiologic conditions and contribute to homeostasis but, when produced in excess, it may lead to tissue injury and organ dysfunction. The regulation of NOS activity and expression is becoming increasingly understood. NOS enzyme inhibitors as tools to decrease excessive NO synthesis have received the most attention and have been subjected to the greatest experimental study. Compounds that scavenge excessive NO have been developed and have shown promise in a number of experimental models but have received considerably less attention as potential therapeutic agents. In this article, the use of NO scavengers in two conditions in which excessive NO appears to be pathophysiologically significant, shock and sepsis, is reviewed. The relevant biology of NO in these disease states is presented and the therapeutic potential of NO scavengers in clinical care is explored.
Export Options
About this article
Cite this article as:
Harbrecht G. Brian, Therapeutic Use of Nitric Oxide Scavengers in Shock and Sepsis, Current Pharmaceutical Design 2006; 12 (27) . https://dx.doi.org/10.2174/138161206778343000
DOI https://dx.doi.org/10.2174/138161206778343000 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Development of Cannabinoid CBII Receptor Agonists for the Treatment of Central Neuropathies
Central Nervous System Agents in Medicinal Chemistry Mitochondria-Mediated Oxidative Stress: Old Target for New Drugs
Current Medicinal Chemistry Limitations and Potential Clinical Application on Contrast Echocardiography
Current Cardiology Reviews Cancer Neovascularization and Proinflammatory Microenvironments
Current Cancer Drug Targets Low Estimated Glomerular Filtration Rate is Associated with High Recurrence Rate and Poor Prognosis of Hemorrhage Stroke
Current Neurovascular Research Obesity and Gastrointestinal Hormones-Dual Effect of Angiotensin II Receptor Blockade and a Partial Agonist of PPAR-γ
Current Vascular Pharmacology Cellular Mechanisms for Diastolic Dysfunction in the Human Heart
Current Pharmaceutical Biotechnology Postoperative Care of the Transplanted Patient
Current Cardiology Reviews Is there a Role for Oral Triple Therapy in Patients with Acute Coronary Syndromes Without Atrial Fibrillation?
Current Vascular Pharmacology Pharmacogenomics and Sepsis-Induced Renal Failure: Effects of β 2-Adrenoceptor Function on the Course of Sepsis
Current Pharmacogenomics and Personalized Medicine Retrometabolic Syntheses of Astaxanthin (3,3-dihydroxy-β,β-carotene-4,4-dione) Conjugates: A Novel Approach to Oral and Parenteral Cardioprotection
Cardiovascular & Hematological Agents in Medicinal Chemistry Drug in Adhesive Transdermal Formulation of Valsartan and Nifedipine: Pharmacokinetics and Pharmacodynamics in Rats
Current Drug Therapy Novel Inflammatory Biomarkers in Coronary Artery Disease: Potential Therapeutic Approaches
Current Medicinal Chemistry Molecular Targets of FTY720 (Fingolimod)
Current Molecular Medicine Prevalence, Incidence, Risk and Protective Factors of Amnestic Mild Cognitive Impairment in the Elderly in Shanghai
Current Alzheimer Research Prevention of Ischemic Stroke: Antithrombotic Therapy in Cardiac Embolism
Current Drug Targets What’s Age Got to do with it? A Review of Contemporary Revascularization in the Elderly
Current Cardiology Reviews Selective Serotonin Re-Uptake Inhibitors for the Treatment of Depression in Coronary Artery Disease and Chronic Heart Failure: Evidence for Pleiotropic Effects
Cardiovascular & Hematological Agents in Medicinal Chemistry Role of Heat Shock Proteins in Atherosclerosis and Atrial Fibrillation
Current Immunology Reviews (Discontinued) Increased Neutrophil-to-lymphocyte Ratios are Associated with Greater Risk of Hemorrhagic Transformation in Patients with Acute Ischemic Stroke
Current Neurovascular Research